Darunavir/cobicistat

Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[2] It contains darunavir and cobicistat.[2][4][5] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[5][2]

Darunavir/cobicistat
Combination of
DarunavirHIV protease inhibitor
CobicistatCytochrome P450 (CYP3A) inhibitor
Clinical data
Trade namesRezolsta, Prezcobix
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC67H90N10O12S3
Molar mass1323.70 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
InChI
  • InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1
  • Key:CXORHDVSJFELCV-HWDLLDTBSA-N

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[3][6][7][2][8]

References
  1. "Cobicistat / darunavir (Prezcobix) Use During Pregnancy". Drugs.com. 25 June 2019. Retrieved 19 February 2020.
  2. "Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Retrieved 20 February 2020.
  3. "Rezolsta EPAR". European Medicines Agency (EMA). Retrieved 4 April 2020.
  4. "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 3 March 2020. Retrieved 29 June 2018.
  5. "Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Retrieved 19 February 2020.
  6. "Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Retrieved 19 February 2020.
  7. "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. 30 January 2015.
  8. "Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Retrieved 4 April 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.